Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Sareum Holdings Plc (SAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013620
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhibitor Library). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (Checkpoint Kinase 1), Aurora+FLT3 kinase, VEGFR-3 (FLT4) kinase, Fatty Acid Synthase (FASN), Tyrosine kinase 2 (TYK2), ALK Kinase, FLT3 and Microtubule binding agents. Sareum’s Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Pampisford Cambridge, the UK.

Sareum Holdings Plc (SAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Sareum Holdings Enters Into Co-Development Agreement With The CRT Pioneer Fund And Bacit 10
Sareum And SRI International Enter Into Co-Development Agreement For Autoimmune And Inflammatory Diseases 12
Licensing Agreements 13
Sareum Holdings Enters Into Licensing Agreement With Hebei Medical University For Aurora+FLT3 Programme 13
Equity Offering 15
Sareum Holdings Raises USD1 Million in Private Placement of Shares 15
Sareum Raises USD1.6 Million in Private Placement of Shares 16
Sareum Raises USD2.2 Million in Private Placement of Shares 17
Sareum to Raise USD0.9 Million in Private Placement of Shares 18
Sareum Holdings Announces Private Placement Of Shares For US$2.7 Million 19
Sareum Decreases Size Of Private Placement Of Shares For US$0.6 Million 20
Sareum Holdings Completes Second Tranche Of Private Placement Of Shares For US$0.04 Million 21
Sareum Holdings Completes Private Placement Of US$0.8 Million 22
Sareum Holdings Plc – Key Competitors 23
Sareum Holdings Plc – Key Employees 24
Sareum Holdings Plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Oct 19, 2017: Sareum Holdings: Final Results for the year ended 30 June 2017 26
Feb 20, 2017: Sareum Holdings Announces Half-Yearly Results For The Six Months Ended 31 December 2016 27
Nov 02, 2016: Sareum Holdings: Final Results 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sareum Holdings Plc, Deals By Therapy Area, 2011 to YTD 2017 8
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Sareum Holdings Enters Into Co-Development Agreement With The CRT Pioneer Fund And Bacit 10
Sareum And SRI International Enter Into Co-Development Agreement For Autoimmune And Inflammatory Diseases 12
Sareum Holdings Enters Into Licensing Agreement With Hebei Medical University For Aurora+FLT3 Programme 13
Sareum Holdings Raises USD1 Million in Private Placement of Shares 15
Sareum Raises USD1.6 Million in Private Placement of Shares 16
Sareum Raises USD2.2 Million in Private Placement of Shares 17
Sareum to Raise USD0.9 Million in Private Placement of Shares 18
Sareum Holdings Announces Private Placement Of Shares For US$2.7 Million 19
Sareum Decreases Size Of Private Placement Of Shares For US$0.6 Million 20
Sareum Holdings Completes Second Tranche Of Private Placement Of Shares For US$0.04 Million 21
Sareum Holdings Completes Private Placement Of US$0.8 Million 22
Sareum Holdings Plc, Key Competitors 23
Sareum Holdings Plc, Key Employees 24
Sareum Holdings Plc, Subsidiaries 25

★海外企業調査レポート[Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TransMontaigne Partners LP (TLP):企業の財務・戦略的SWOT分析
    Summary TransMontaigne Partners LP (TLP), a subsidiary of TransMontaigne GP LLC is an energy infrastructure service provider that offers integrated terminaling, transportation, and storage services. The company distributes and transports crude oil, chemicals, petroleum products, fertilizers, and oth …
  • HUP-Zagreb d.d.:企業の戦略・SWOT・財務情報
    HUP-Zagreb d.d. - Strategy, SWOT and Corporate Finance Report Summary HUP-Zagreb d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • AB Volvo:戦略・SWOT・企業財務分析
    AB Volvo - Strategy, SWOT and Corporate Finance Report Summary AB Volvo - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • SREI Infrastructure Finance Ltd:企業のM&A・事業提携・投資動向
    SREI Infrastructure Finance Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SREI Infrastructure Finance Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Meridian Bioscience Inc (VIVO):企業の財務・戦略的SWOT分析
    Meridian Bioscience Inc (VIVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • KACO new energy GmbH:企業の戦略的SWOT分析
    KACO new energy GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Apex Biotechnology Corp (1733)-医療機器分野:企業M&A・提携分析
    Summary Apex Biotechnology Corp (ApexBio) is a medical device company that develops, manufactures and commercializes biosensor-based blood glucose monitoring systems. The company provides patient self-testing products, point of care diagnostics and multi-functional products. It also imports and expo …
  • ERI Bancaire SA:企業の戦略的SWOT分析
    ERI Bancaire SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • 21st Century Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary 21st Century Oncology Inc. (21st Century Oncology), a subsidiary of 21st Century Oncology Holdings, Inc., is a provider of integrated cancer care services (ICC). It operates through an integrated network of cancer treatment centers and affiliated physicians with specialization in radiation o …
  • Arabian Shield Cooperative Insurance Company:企業の戦略・SWOT・財務情報
    Arabian Shield Cooperative Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Arabian Shield Cooperative Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Great Panther Silver Limited:企業の戦略・SWOT・財務情報
    Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report Summary Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Vital Images Inc:企業の戦略的SWOT分析
    Vital Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • First Data Corp (FDC):企業の財務・戦略的SWOT分析
    First Data Corp (FDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Intuitive Surgical Inc (ISRG):医療機器:M&Aディール及び事業提携情報
    Summary Intuitive Surgical Inc (Intuitive Surgical) is a provider of robotic-assisted minimally invasive surgery (MIS) devices. Its portfolio encompasses da Vinci Surgical Systems, InSite and Firefly Fluorescence imaging systems (Firefly), instruments and accessories and training technologies. The d …
  • Microbot Medical Inc (MBOT):企業の財務・戦略的SWOT分析
    Summary Microbot Medical Inc (Microbot), formerly StemCells Inc, is a pre-clinical medical device company that researches, designs and develops micro-robotics assisted medical technologies for minimally invasive surgeries. The company’s product candidates include Self Cleaning Shunt, intended for th …
  • Myriad Genetics Inc (MYGN):医療機器:M&Aディール及び事業提携情報
    Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, t …
  • Nexstar Media Group, Inc. (NXST):企業の財務・戦略的SWOT分析
    Nexstar Media Group, Inc. (NXST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Microsemi Corp:企業の戦略的SWOT分析
    Microsemi Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Volta River Authority:企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (874):企業の財務・戦略的SWOT分析
    Summary Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Guangzhou Baiyunshan Pharmaceutical) is a manufacturer of herbal medicine, chemical raw material medicine and preparation, biological medicine, and health products. The company also offers health medicines, health beverages, Chinese and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆